ARS Pharmaceuticals, Inc. (SPRY) stock
SPRYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.81−0.14 (-3.54%)
Close on Nov 12, 2026Market cap $378.89MP/E –Yield –
ARS Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
ARS Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was -161.5%. For fiscal 2025 it was -212.9%, against -3.5% the year before. The highest annual figure on record is -3.5% in fiscal 2024.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -212.9% | −209.5 |
| FY2024 | Dec 31, 2024 | -3.5% | +225063.2 |
| FY2023 | Dec 31, 2023 | -225066.7% | −222367.9 |
| FY2022 | Dec 31, 2022 | -2698.8% | −2345.5 |
| FY2021 | Dec 31, 2021 | -353.3% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -90.6% | +73.0 |
| Q2 FY2026 | Jun 30, 2026 | -182.6% | +120.3 |
| Q1 FY2026 | Mar 31, 2026 | -265.2% | +201.1 |
| Q4 FY2025 | Dec 31, 2025 | -147.6% | −202.1 |
| Q3 FY2025 | Sep 30, 2025 | -163.7% | +888.0 |
| Q2 FY2025 | Jun 30, 2025 | -302.9% | +2765.1 |
| Q1 FY2025 | Mar 31, 2025 | -466.3% | +205563.7 |
| Q4 FY2024 | Dec 31, 2024 | 54.5% | +93619.5 |
| Q3 FY2024 | Sep 30, 2024 | -1051.6% | +2456.3 |
| Q2 FY2024 | Jun 30, 2024 | -3068.0% | −1700.8 |
| Q2 FY2023 | Jun 30, 2023 | -206030.0% | −204959.3 |
| Q1 FY2023 | Mar 31, 2023 | -93565.0% | – |
| Q3 FY2022 | Sep 30, 2022 | -3507.9% | – |
| Q2 FY2022 | Jun 30, 2022 | -1367.2% | – |
| Q1 FY2022 | Mar 31, 2022 | -1070.7% | – |
See a number that looks wrong?